Exact Sciences Corp.(EXAS),a molecular diagnostics company focusing on the early detection of colorectal cancer, Tuesday said that it had decided to sell its common stock shares through an under written public offering. The company, however did not disclose the size or price of the offering.
Jefferies & Company, Inc. and Robert W. Baird & Co. Inc. are acting as joint book-running managers for the offering, said Exact Sciences.
On Tuesday, Exact Sciences Corp closed at $10.29 per share on the NASDAQ.
For comments and feedback: editorial@rttnews.com